138 related articles for article (PubMed ID: 10470230)
1. Multicenter evaluation of the Elecsys CA 125 II assay.
Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
[TBL] [Abstract][Full Text] [Related]
2. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis.
Koper NP; Thomas CM; Massuger LF; Segers MF; Kiemeney LA; Verbeek AL
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):617-23. PubMed ID: 9298352
[TBL] [Abstract][Full Text] [Related]
4. Multicenter evaluation of a new immunoassay for intact PTH measurement on the Elecsys System 2010 and 1010.
Hermsen D; Franzson L; Hoffmann JP; Isaksson A; Kaufman JM; Leary E; Müller C; Nakatsuka K; Nishizawa Y; Reinauer H; Riesen W; Roth HJ; Steinmüller T; Troch T; Bergmann P
Clin Lab; 2002; 48(3-4):131-41. PubMed ID: 11934215
[TBL] [Abstract][Full Text] [Related]
5. Results from a multicenter evaluation of the 4th generation Elecsys Troponin T assay.
Hermsen D; Apple F; Garcia-Beltràn L; Jaffe A; Karon B; Lewandrowski E; Mühlbacher A; Müller R; Ordóñez J; Pagani F; Panteghini M; Plecko T; Jarausch J
Clin Lab; 2007; 53(1-2):1-9. PubMed ID: 17323819
[TBL] [Abstract][Full Text] [Related]
6. Performance characteristics of seven automated CA 125 assays.
Mongia SK; Rawlins ML; Owen WE; Roberts WL
Am J Clin Pathol; 2006 Jun; 125(6):921-7. PubMed ID: 16690492
[TBL] [Abstract][Full Text] [Related]
7. Technical evaluation of three second generation CA 125 assays.
Bonfrer JM; Baan AW; Jansen E; Lentfer D; Kenemans P
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):201-7. PubMed ID: 8031969
[TBL] [Abstract][Full Text] [Related]
8. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
9. Elecsys CEA, PSA and AFP. Clinical results of a multicentre evaluation.
Uhl W; Chan DW; Jones K; Kelley C; Assmann G; von Eckardstein A; Sägers A; Yvert JP; Schneider AM; Torralba A; Fuentes-Arderiu X; Gonzalez de la Presa B; Vives M; Greiling H; Eberle A; Niederau CM; Cremer P; Reiter W; Vogeser M; Neumeier D; Luppa P; Huber U
Wien Klin Wochenschr; 1998; 110 Suppl 3():51-61. PubMed ID: 9677672
[TBL] [Abstract][Full Text] [Related]
10. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P
Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806
[TBL] [Abstract][Full Text] [Related]
11. Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125.
van Ingen HE; Chan DW; Hubl W; Miyachi H; Molina R; Pitzel L; Ruibal A; Rymer JC; Domke I
Clin Chem; 1998 Dec; 44(12):2530-6. PubMed ID: 9836722
[TBL] [Abstract][Full Text] [Related]
12. Proposed reference value of the CA 125 tumour marker in men. Potential applications in clinical practice.
Barceló B; Ayllón O; Belmonte M; Barceló A; Vidal R; Forteza-Rey J; Gutiérrez A
Clin Biochem; 2008 Jun; 41(9):717-22. PubMed ID: 18371306
[TBL] [Abstract][Full Text] [Related]
13. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
14. Performance characteristics of IMMULITE TPS: a comparison with TPS IRMA.
Einarsson R; Lei JD; Ullrich A; Van Dalen A
Anticancer Res; 1999; 19(4A):2743-7. PubMed ID: 10470233
[TBL] [Abstract][Full Text] [Related]
15. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661
[TBL] [Abstract][Full Text] [Related]
16. A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.
Römer M; Haeckel R; Brux B; Sinha P; Raiko I; Krieg M; Stark M; Seidel D; Hübner U; Schmitz G
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):637-44. PubMed ID: 9298356
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
18. The second generation CA 125 assays.
Kenemans P; Verstraeten AA; van Kamp GJ; von Mensdorff-Pouilly S
Ann Med; 1995 Feb; 27(1):107-13. PubMed ID: 7741988
[TBL] [Abstract][Full Text] [Related]
19. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
[TBL] [Abstract][Full Text] [Related]
20. Analytical performance of Elecsys 2010--a multicentre evaluation.
Stockmann W; Bablok W; Luppa P
Wien Klin Wochenschr; 1998; 110 Suppl 3():10-21. PubMed ID: 9677668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
